Citizenship United Kingdom Residence United Kingdom | Name Mark Walport | |
![]() | ||
Born Mark Jeremy Walport 25 January 1953 (age 71) London ( 1953-01-25 ) Institutions Hammersmith HospitalRoyal Brompton HospitalGuy's HospitalImperial College School of MedicineWellcome TrustUniversity of CambridgeGovernment of the United Kingdom Notable awards Roche Rheumatology Prize (1991)Graham Bull Prize in Clinical Science (1996)FMedSci (1998)Knight Bachelor (2009)FRS (2011) | ||
Sir mark walport s opening keynote at openoxford
Sir Mark Jeremy Walport HonFRSE (born 25 January 1953) is a medical scientist and the Government Chief Scientific Adviser in the United Kingdom.
Contents
- Sir mark walport s opening keynote at openoxford
- Sir mark walport let s embed genomics in the nhs full wired health talk
- Education
- Career
- Honours
- References

Sir mark walport let s embed genomics in the nhs full wired health talk
Education

Walport is the son of a general practitioner and was born in London. He was educated at St Paul's School, London, studied medicine at Clare College, Cambridge, and completed his clinical training at Hammersmith, Guy's and Brompton Hospitals in London. He was awarded a PhD for research into complement receptors under the supervision of Peter Lachmann in 1986 at the University of Cambridge.
Career

Previously Walport was Director of the Wellcome Trust from 2003 to 2013. Before this, he was Professor of Medicine (from 1991) and Head of the Division of Medicine (from 1997) at Imperial College London, where he led a research team that focused on the immunology and genetics of rheumatic diseases.

Walport was appointed to be the eleventh Government Chief Scientific Adviser in 2013, succeeding Sir John Beddington. As of September 2015, in this role Walport was paid a salary of between £155,000 and £159,999, making him one of the 328 most highly paid people in the British public sector at that time.
It was announced in February 2017 that Mark Walport is now Chief Executive Designate of UK Research and Innovation (UKRI).
Honours
Walport was knighted in the 2009 New Year Honours list for services to medical research. He was elected an Honorary Fellow of the Royal Society of Edinburgh in 2017 and a Fellow of the Royal Society in 2011. His nomination for the Royal Society reads:
Mark Walport has an overwhelming case for election both for his earlier scientific work on the immunology of systemic LE and the role of complement and of defective apoptosis in its pathogenesis; and, as a general candidate, for his achievements as head of medicine at the Hammersmith Campus of Imperial College and since 2003 as Director of the Wellcome Trust. In the latter role he has provided national and international leadership at the highest level on biomedical research and policy issues and is widely recognised as a world leader in the promotion of biomedical science.